Hoffmann-La Roche Inc.

Janssen Pharmaceutica Nv

Janssen Biotech, Inc.

Riboscience LLC

F. Hoffmann-La Roche Ag

European Molecular Biology Laboratory

Savira Pharmaceuticals Gmbh

Zhuming Zhang

Jing Zhang

Jin-Jun Liu

Song Yang

Li Chen

Qingjie Ding

Xin-Jie Chu

Nan Jiang

Lieven Meerpoel

Peter J Connolly

Kin-Chun Thomas Luk

Gilles C Bignan

Xingchun Han

Norman Kong

Vineet Pande

David Joseph Bartkovitz

John Anthony Moliterni

Nicholas J S Huby

Christian Rocaboy

Ian Hickson

Jonathan Branch

Luis B Trabalón Escolar

Scott D Kuduk

Sung-Sau So

Aihua Wang

Mark Smith

Tina Morgan Ross

Lee Apostle McDermott

Lindsey DeRatt

Jefferson Wright Tilley

Helmut Heinrich Buschmann

Ronald Charles Hawley

Yun He

Yi Ren

Achyutharao Sidduri

Francisco Xavier Talamas

Peter Michael Wovkulich

Steven Gregory Mischke

Robert Alan Goodnow, Jr

Nader Fotouhi

Giacomo Pizzolato

Shaoqing Chen

Kshitij Chhabilbhai Thakkar

Stephen Cusack

Bradford Graves

Norbert Handler

Oliver Szolar

Andrea Wolkerstorfer

Hong Wang

Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R, R, R, R, X, and Y are defined herein.

Dihydroorotate dehydrogenase inhibitors

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein Rand G are defined herein.

Substituted thiohydantoin derivatives as androgen receptor antagonists

The present invention relates to the use of 3'-fluoro, 4&#x2032;-azido nucleoside phosphoramidate prodrug derivatives of formula I wherein the symbols are as defined in the specification, to pharmaceutically acceptable salts thereof, and to pharmaceutical compositions containing such compounds for the treatment of HCV.

4'-azido, 3&#x2032;-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication

The present disclosure relates to compounds of Formula (I): Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of using the compounds of Formula (I) and/or compositions comprising the compounds of Formula (I) for the treatment of HCV. 

2', 4&#x2032;-difluoro-2&#x2032;-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication

The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease

There are provided compounds of the formula wherein X, Y, R, R, R, R, R, R, Rand Rare as described hereinand enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

Substituted pyrrolidine-2-carboxamides

There is provided a compound of the formula 

Substituted spiroindolinones

There are provided compounds of the formula or a pharmaceutically acceptable salt or ester thereof wherein X, Y, R, Rare as herein described. The compounds have utility as antiproliferative agents, especially, as anticancer agents.

Spiroindolinone derivatives

There are provided compounds of the formula wherein X, Y and Rto Rare as described herein and the enantiomers and pharmaceutically acceptable salts and esters thereof which compounds have anticancer activity.

Spiroindolinone pyrrolidines

There are provided compounds of the formula and pharmaceutically acceptable salts and esters thereof The compounds are useful as anticancer agents.

There are provided compounds of the formula wherein X, Y and Rto Rare described herein along with the enantiomers, pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

There are provided compounds of the formula or a pharmaceutically acceptable salt or ester thereof wherein X, Y, W, W', V, V&#x2032;, V&#x2033;, R, Rand Rare as herein described. The compounds have utility as antiproliferative agents, especially, as anticancer agents.

3,3'-spiroindolinone derivatives

Growing community of inventors

Hillsborough, NJ, United States of America

Zhuming Zhang